IMU Biosciences
Immune profiling diagnostics, London
High-definition immune profiling platform for diagnosis and treatment monitoring. It raised £40m in its Series A in June 2026. It has 1 role open, 1 of them in the UK.
Backed by British Business Bank, IQ Capital, Meltwind and Molten Ventures.
Not found on the Home Office register of licensed visa sponsors.
- 6 daystypical age of an open role
- 0roles open for more than 60 days
- 5roles taken down since we started tracking
- 0%of roles list a salary
Open roles
1 live today- Salary not listed6 days agoApply
Open roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
Open roles by team
As the company labels themIn the news
All 8 stories- OtherGenomeWeb, 14 days agoIMU Biosciences to Generate Single-Cell Immune Profiling Data for 80K UK Biobank Blood Samples
- OtherBigGo Finance, 14 days agoIMU Biosciences' John Baker: 80,000 UK Biobank Blood Samples and the Push to Predict Who Responds to Cancer Immunotherapy
- OtherPR Newswire, 14 days agoUltima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation
- Partnerships & dealsYahoo Finance, 9 Sept 2026IMU Biosciences and Eurofins Transplant Genomics Form Strategic Partnership to Advance Transplant-Related Clinical Development Programmes
- Partnerships & dealsBioPharma APAC, 26 Jun 2026Waters and IMU Biosciences Partner to Advance AI-Powered High-Definition Immune Profiling
- OtherPR Newswire, 24 Jun 2026IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine